Ozempic really could turn back the clock on your biological age

Evidence for Ozempic’s Broad Health Benefits: New Study Shows Promising Results

The latest research on the type 2 diabetes drug Ozempic has revealed exciting findings regarding its impact on ageing. Ozempic, along with Wegovy, contains semaglutide, a medication that has shown potential beyond treating diabetes and obesity.

Previous studies hinted at the possibility of these drugs delaying biological ageing, and now, a new clinical trial has provided concrete evidence to support this claim. According to Varun Dwaraka from TruDiagnostic in Kentucky, the study results offer a significant breakthrough in understanding the anti-ageing effects of Ozempic.

Epigenetic clocks were used to assess the drug’s impact on biological ageing by analyzing DNA methylation patterns. In a trial involving individuals with HIV-associated lipohypertrophy, those who received Ozempic showed an average biological age reduction of 3.1 years compared to the placebo group.

The study also highlighted the drug’s positive effects on various organs and systems, particularly in slowing down ageing in the heart, kidneys, inflammatory system, and brain. Dwaraka attributes these outcomes to semaglutide’s ability to improve fat distribution and metabolic health, consequently reducing inflammation and pro-ageing molecules.

While the study focused on a specific population, the implications extend to broader age-related issues. Randy Seeley from the University of Michigan Medical School emphasizes that the benefits of Ozempic stem from its overall impact on cellular metabolism and inflammation, both of which play a significant role in the ageing process.

Although the idea of using semaglutide as an anti-ageing therapy is still premature, Dwaraka believes that repurposing existing drugs for age-related conditions holds promise. The study’s findings pave the way for further exploration of Ozempic and similar medications in addressing age-related health concerns.